21 CFR Part 11 and EU GMP Annex 11 Compliance Guide
FDA 21 CFR Part 11 and EU GMP Annex 11 are the two primary regulatory frameworks governing electronic records and computerised systems in pharmaceutical manufacturing. Understanding their differences — and where they align — is essential for any digital transformation project in a GMP environment.
Electronic records and audit trail requirements
21 CFR Part 11 requires that electronic records be protected from modification, with audit trails capturing original and changed values, user identity, timestamp and reason for change. EU GMP Annex 11 adds that audit trail review must be part of the batch release process. Both require validated access controls, unique user IDs and authorisation checks.
Electronic signature requirements
Electronic signatures under Part 11 must be linked to their records, cannot be transferred to another document, and must include the printed name, date/time and meaning of the signature act. Annex 11 requires that e-signature procedures be documented and that the system prevents signature by an unauthorised user.
Validation evidence for dual compliance
Manufacturing for both US and EU markets requires addressing both frameworks. System validation documentation should reference both Part 11 and Annex 11 requirements in the URS, risk assessment, configuration specification and test protocols. A gap assessment comparing both standards to the system design is required before IQ/OQ/PQ.
How to use this page
Use this 21 CFR Part 11 and EU GMP Annex 11 Compliance Guide page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.
Evidence to prepare
For 21 CFR Part 11 and EU GMP Annex 11 Compliance Guide, prepare the records, owners, risks and decision criteria linked to electronic records and audit trail requirements, electronic signature requirements, validation evidence for dual compliance. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.
Frequently asked questions
What is the key difference between 21 CFR Part 11 and EU GMP Annex 11?
21 CFR Part 11 (FDA) focuses specifically on electronic record and electronic signature controls for FDA-regulated operations. EU GMP Annex 11 covers the full lifecycle of computerised systems in GMP environments — including supplier assessment, validation methodology, business continuity, legacy systems and cloud services. Part 11 is narrower in scope but equally strict on record authenticity. For dual-market manufacturers, both must be addressed in the validation package.
What are the minimum audit trail requirements under 21 CFR Part 11?
Under 21 CFR Part 11, audit trails must: capture original and changed values for GxP-relevant records, record user identity, date/time of change and reason for change, be computer-generated (not editable by users), be retained for the duration required by the underlying GMP record, and be reviewed as part of the batch review or release process. The audit trail must not be disabled by operators.
Can cloud-based MES or LIMS systems be used in a 21 CFR Part 11 environment?
Yes, but with additional validation requirements. Cloud systems must demonstrate data residency controls, backup and recovery procedures, access control segregation, audit trail integrity, and incident response capabilities. The system owner remains responsible for validation even when using a SaaS system — suppliers provide documentation that must be assessed and supplemented with site-specific validation evidence. EU GMP Annex 11 sections 3 and 17 specifically address outsourced and cloud-hosted systems.